Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Athe crawled time : 03:00 save search
Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology
Published: 2023-04-25 (Crawled : 03:00) - alteritytherapeutics.com
ATHE | $2.33 9.39% 8.58% 170K
|
Health Technology
|
| O: -0.14%
H: 0.35%
C: -1.07%
natural sensor therapeutics study
Appendix 4C – Q3 FY23 Quarterly Cash Flow Report
Published: 2023-04-27 (Crawled : 03:00) - alteritytherapeutics.com
ATHE | $2.33 9.39% 8.58% 170K
|
Health Technology
|
| O: -1.79%
H: 3.64%
C: 0.36%
fy23 report flow
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy
Published: 2023-01-09 (Crawled : 03:00) - alteritytherapeutics.com
ATHE | $2.33 9.39% 8.58% 170K
|
Health Technology
|
| O: 1.46%
H: 2.22%
C: -2.82%
ath434 treatment system trial therapeutics
Chairman’s Address 2022 Annual General Meeting
Published: 2022-11-11 (Crawled : 03:00) - alteritytherapeutics.com
ATHE | $2.33 9.39% 8.58% 170K
|
Health Technology
|
| O: -1.15%
H: 8.03%
C: 7.98%
meeting
Alterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting
Published: 2022-11-07 (Crawled : 03:00) - alteritytherapeutics.com
ATHE | $2.33 9.39% 8.58% 170K
|
Health Technology
|
| O: 2.78%
H: 1.08%
C: 1.08%
meeting therapeutics presentation study
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy
Published: 2022-10-13 (Crawled : 03:00) - alteritytherapeutics.com
ATHE | $2.33 9.39% 8.58% 170K
|
Health Technology
|
| O: -4.1%
H: 6.41%
C: 6.34%
ath434 treatment system australia trial therapeutics phase 2
Appendix 4C – Q4 FY22 Quarterly Cash Flow Report
Published: 2022-07-22 (Crawled : 03:00) - alteritytherapeutics.com
ATHE | $2.33 9.39% 8.58% 170K
|
Health Technology
|
| O: -4.58%
H: 7.57%
C: 4.83%
fy22 report flow
Alterity Therapeutics to Participate in the Benchmark Company Healthcare House Call Conference
Published: 2022-05-26 (Crawled : 03:00) - alteritytherapeutics.com
ATHE | $2.33 9.39% 8.58% 170K
|
Health Technology
|
| O: 4.14%
H: 3.09%
C: -1.38%
conference therapeutics house
Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom
Published: 2022-04-27 (Crawled : 03:00) - alteritytherapeutics.com
ATHE | $2.33 9.39% 8.58% 170K
|
Health Technology
|
| O: 0.7%
H: 2.6%
C: -2.0%
ath434 trial therapeutics authorization phase 2
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.